Denali Therapeutics Inc.
DNLIHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeDenali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. With a market capitalization of $3.70B, it sits in mid-cap territory. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome).
Market Cap
$3.70B
Beta
0.96
P/E (TTM)
—
P/E (Fwd)
-9.37
EPS (TTM)
$-2.95
EPS (Fwd)
$-2.49
ROE
-49.6%
ROA
-27.0%
Cash
$987.7M
Total Debt
$40.0M
Free CF
-$190.3M
52W Change
66.4%
Annual Financials
Cash vs Debt
Denali Therapeutics Inc. holds $987.7M in cash against $40.0M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$190.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -49.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $108.5M (2022) to $0 (2025), a 100% decline worth watching.
With cash comfortably exceeding debt, DNLI has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing DNLI's risk profile alongside its fundamentals and technical indicators provides a more complete picture.